Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/1b, Open-label, Multicenter, Dose Escalation and Dose Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of KQB198 as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hematologic Malignancies

NCT06645886 is registered in ClinicalTrials.gov with Kumquat Biosciences Inc. as lead sponsor.

NCT NCT06645886
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06645886 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/1b, Open-label, Multicenter, Dose Escalation and Dose Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of KQB198 as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hematologic Malignancies
Lead sponsor
Kumquat Biosciences Inc.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
December 9, 2024
Completion date
March 31, 2027
Enrollment
13 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

adult, hematologic malignancies